Data from a phase 1, first-in-human trial of NI006 suggests the agent could have a potential role in the management of transthyretin amyloid cardiomyopathy.
The recombinant human antibody NI006 was safe for the treatment of transthyretin amyloid cardiomyopathy in a small phase 1 trial and may also reduce amyloid protein accumulation in the heart.